Shots:
In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response
In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…
